Patents by Inventor Eric A. Voight

Eric A. Voight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024338
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: June 14, 2023
    Publication date: January 25, 2024
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao., Xiaochun Lou, Sean Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
  • Publication number: 20230106081
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 6, 2023
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
  • Publication number: 20220251123
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 2, 2021
    Publication date: August 11, 2022
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20220153765
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: July 16, 2021
    Publication date: May 19, 2022
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
  • Patent number: 11149043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 19, 2021
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210300863
    Abstract: A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C).
    Type: Application
    Filed: August 1, 2019
    Publication date: September 30, 2021
    Applicant: Intervet Inc.
    Inventors: Eric Voight, Christophe Pierre Alain Chassaing, Hans Peter Niedermann, Stephan Veit, Claudia Scheipers
  • Patent number: 11091507
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 17, 2021
    Assignee: AbbVie Inc.
    Inventors: Brian P. Enright, Ye Huang, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Peter T. Mayer, Christopher P. Miller, Valentino J. Stella, Eric A. Voight
  • Publication number: 20210230195
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20200262852
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: May 4, 2020
    Publication date: August 20, 2020
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff Zhang
  • Patent number: 10730895
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 4, 2020
    Assignee: AbbVie Inc.
    Inventors: Philip R. Kym, Eric A. Voight
  • Publication number: 20190375770
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 12, 2019
    Applicant: AbbVie Inc.
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla E. Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christiopher P. Miller, James Stambuli, Valentino J. Stella, Eric A. Voight, Zhi Wang, Geoff G. Zhang
  • Publication number: 20190358214
    Abstract: The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 28, 2019
    Applicant: AbbVie Inc.
    Inventors: Brian Brown, Hui-Ju Chen, David DeGoey, Geoff Halvorsen, John Hartung, Howard R. Heyman, Nathan Ide, Dale Kempf, Allen C. Krueger, Tao Li, Tongmei Li, Steven R. Martinez, Christopher C. Marvin, John T. Randolph, Eric Voight, Rolf Wagner, Jaclyn Chau
  • Publication number: 20190224220
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: April 20, 2017
    Publication date: July 25, 2019
    Applicant: AbbVie Inc.
    Inventors: Philip R. Kym, Eric Voight
  • Publication number: 20190135827
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Publication number: 20190127356
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Patent number: 10174061
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: January 8, 2019
    Assignee: ABBVIE INC.
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Brian P. Enright, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
  • Patent number: 10053474
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 21, 2018
    Assignee: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Publication number: 20180079762
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: September 26, 2017
    Publication date: March 22, 2018
    Applicant: AbbVie Inc.
    Inventors: Benoit Cardinal-David, Vincent S. Chan, Kassibla Dempah, Brian P. Enright, Rodger F. Henry, Raimundo Ho, Ye Huang, Alexander D. Huters, Russell C. Klix, Scott W. Krabbe, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
  • Publication number: 20180037587
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: October 17, 2017
    Publication date: February 8, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
  • Publication number: 20180022763
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: May 5, 2017
    Publication date: January 25, 2018
    Applicant: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman